PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
PEN's expanding thrombectomy portfolio and global push fuel growth, but FX headwinds and macro risks may pressure near-term profitability.
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
Blair William and Co. IL cut its holdings in Penumbra, Inc. (NYSE: PEN) by 23.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,108 shares of the company's stock after selling 2,456 shares during the quarter. Blair William and Co. IL's holdings
Penumbra jumps after Q4 earnings and revenue beat, with double-digit sales growth, margin expansion and strong U.S. performance across key product lines.
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.